Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real World, Prospective, Single-center, Observational Study Comparing Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab

NCT04837651 is registered in ClinicalTrials.gov with Dragonfly Research, LLC as lead sponsor.

NCT NCT04837651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04837651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real World, Prospective, Single-center, Observational Study Comparing Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab
Lead sponsor
Dragonfly Research, LLC
Phase
Observational
Overall status
Completed
Start date
March 2, 2021
Completion date
July 1, 2021
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, autoimmune diseases of the nervous system, demyelinating autoimmune diseases, cns, demyelinating diseases, immune system diseases, multiple sclerosis, nervous system diseases, pathologic processes